U.S. Markets closed

Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

Mike Benson
Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.